New company Recida to Focus on Developing Therapies Against Antibiotic-resistant Bacteria

Frazier Healthcare Partners has launched a new biopharmaceutical company called Recida Therapeutics, which will develop new therapies for serious antibiotic-resistant infections, including Pseudomonas aeruginosa, the leading cause of lung infections in cystic fibrosis (CF) patients. RC-01 is Recida’s lead therapy candidate for multidrug-resistant Gram-negative bacteria, a group of…